CALR and B-cell non-Hodgkin lymphoma: Furthermore, the dual treatment caused an increase in G2/M phase cells with a concomitant decrease in the number of cells in G1 phase, confirming that the combination of GSK-591 and Ro is synergistically inducing cell cycle arrest in B-cell lymphoma (Supplementary Fig. 3G).